ArticleJournal of the National Comprehensive Cancer Network : JNCCN2019
PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012 U.S. Preventive Services Task Force Guideline Changes.
Article in Journal of the National Comprehensive Cancer Network : JNCCN, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Prostate Cancer Incidence, Mortality, and Survival in Switzerland.JAMA network open · 2026Article
- Challenges in Using Deep Neural Networks Across Multiple Readers in Delineating Prostate Gland Anatomy.Journal of imaging informatics in medicine · 2026Article
- Time to de-implementation of low-value cancer screening practices: a narrative review.BMJ quality & safety · 2025Review
- A pilot randomized clinical trial of a smartphone-based application to support at-home PSA screening and culturally tailored prostate cancer education for African American men: A study protocol.Contemporary clinical trials · 2024Article
- Incidence of prostate cancer in Medicaid beneficiaries with and without HIV in 2001-2015 in 14 states.AIDS care · 2024Article
- Prostate cancer screening with Prostate-Specific Antigen (PSA) testing: A retrospective study.Pakistan journal of medical sciences · 2024Article
- Prostate cancer screening in African American men: a review of the evidence.Journal of the National Cancer Institute · 2024Review
- A Review of Research Studies Using Data from the Administrative Claims Databases in Japan.Drugs - real world outcomes · 2022Review
- Expanding the Secondary Use of Prostate Cancer Real World Data: Automated Classifiers for Clinical and Pathological Stage.Frontiers in digital health · 2022Article
- The Utilization and Costs of Grade D USPSTF Services in Medicare, 2007-2016.Journal of general internal medicine · 2021Article
- Racial and Ethnic Disparities in the Use of Prostate Magnetic Resonance Imaging Following an Elevated Prostate-Specific Antigen Test.JAMA network open · 2021Article
- Preferences for More or Less Health Care and Association With Health Literacy of Men Eligible for Prostate-Specific Antigen Screening in Australia.JAMA network open · 2021Article
- Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation.Journal of the National Cancer Institute · 2021Article
- Changes in cancer incidence and outcomes among kidney transplant recipients in the United States over a thirty-year period.Kidney international · 2021Article
- Associations of Prostate-Specific Antigen (PSA) Testing in the US Population: Results from a National Cross-Sectional Survey.Journal of community health · 2021Article
- Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Propensity Score-Matched Analysis.Frontiers in oncology · 2021Article
- Real-world Evidence to Estimate Prostate Cancer Costs for First-line Treatment or Active Surveillance.European urology open science · 2021Article
- Trends in cancer incidence and mortality rates in the United States from 1975 to 2016.Annals of translational medicine · 2020Article
- Leveraging Digital Data to Inform and Improve Quality Cancer Care.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Factors Influencing Uptake of Changes to Clinical Preventive Guidelines.Journal of the American Board of Family Medicine : JABFMArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundMost patients with prostate cancer are diagnosed with low-grade, localized disease and may not require definitive treatment. In 2012, the U.S. Preventive Services Task Force (USPSTF) recommended against prostate cancer screening to address overdetection and overtreatment. This study sought to determine the effect of guideline changes on prostate-specific antigen (PSA) screening and initial diagnostic stage for prostate cancer. PATIENTS AND
methodsA difference-in-differences analysis was conducted to compare changes in PSA screening (exposure) relative to cholesterol testing (control) after the 2012 USPSTF guideline changes, and chi-square test was used to determine whether there was a subsequent decrease in early-stage, low-risk prostate cancer diagnoses. Data were derived from a tertiary academic medical center's electronic health records, a national commercial insurance database (OptumLabs), and the SEER database for men aged ≥35 years before (2008-2011) and after (2013-2016) the guideline changes.
resultsIn both the academic center and insurance databases, PSA testing significantly decreased for all men compared with the control. The greatest decrease was among men aged 55 to 74 years at the academic center and among those aged ≥75 years in the commercial database. The proportion of early-stage prostate cancer diagnoses (<T2) decreased across age groups at the academic center and in the SEER database.
conclusionsIn primary care, PSA testing decreased significantly and fewer prostate cancers were diagnosed at an early stage, suggesting provider adherence to the 2012 USPSTF guideline changes. Long-term follow-up is needed to understand the effect of decreased screening on prostate cancer survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.